Search

News Effect of Etanercept on Structural Changes in the Sacroiliac Joint in Patients with Early Axial Spondyloarthritis

Currently, there is limited evidence regarding the effect of tumor necrosis factor inhibitors on structural lesions in patients with early forms of axial spondyloarthritis (AxSpA). The aim of the study presented below, published in January 2021, was to evaluate structural changes in the sacroiliac joint (SIJ) on magnetic resonance imaging (MRI) after 2 years of treatment with etanercept within the clinical study EMBARK in patients with early AxSpA compared to a control cohort not treated with biologics (DESIR) and to assess the relationship between MRI changes and disease activity according to ASDAS.

Source: Arthritis 14. 8. 2021

News Long-term results of alpha-1-antitrypsin deficiency treatment –⁠ RAPID program

RAPID/RAPID Extension is the largest clinical program to date that has confirmed the benefit of alpha-1-antitrypsin inhibitor in the treatment of chronic obstructive pulmonary disease (COPD) associated with its deficiency.

Source: Deficiency of Alpha-1-Antitrypsin 17. 12. 2020

Články časopisu Highly active antiretroviral therapy during gestation: effects on a rat model of pregnancy

Author of the article: L. P. Carvalho, R. S. Simões, Edward Araujo Júnior, Oliveira Filho R. M., L. Kulay Júnior, M. U. Nakamura Source: Česká gynekologie | 2/2014 21. 4. 2014

News Sport and Physical Activity Benefit Hemophiliacs

Sport and physical activity are beneficial for individuals with hemophilia. This statement was confirmed by a study conducted by German and British authors published in the journal Haemophilia.

Source: Hemophilia 5. 5. 2021

News Efficacy of Romiplostim in Children with Persistent or Chronic ITP

The effect of the thrombopoietin receptor agonist romiplostim in adult patients with immune thrombocytopenia (ITP) is well known. Equally important, however, are data on its treatment in children —⁠ presented by a study whose results were published in the journal Lancet.

Source: Immune Thrombocytopenia 18. 11. 2020

News Genetic Testing in Non-Small Cell Lung Cancer -⁠ Clinical Practice Experience

Targeted therapy has brought significant improvements to certain groups of patients with non-small cell lung cancer (NSCLC). Selecting patients who will benefit from targeted therapy can be performed using molecular profiling with next-generation sequencing (NGS) techniques. However, we still lack sufficient data on the feasibility and results of such profiling in real-world clinical practice, which was the focus of an analysis recently published in The Oncologist.

Source: Genetic Profile and Treatment of NSCLC 30. 9. 2020

News Comparison of the effects of fibrinogen concentrates and fresh frozen plasma in patients with acute traumatic coagulopathy

A quasi-experimental study compared the effectiveness of fibrinogen concentrates and fresh frozen plasma in patients with severe blunt trauma requiring the administration of erythrocyte replacements.

Source: Life-threatening Bleeding 15. 6. 2022

News The role of the physiotherapist in hemophilia care is expanding and irreplaceable −⁠ what it entails and how it changes with treatment advances?

In the team cooperation in caring for patients with hemophilia, the physiotherapist plays a very important role, which is expanding with today's comprehensive approach to treating this condition. The reason is that even in the era of modern treatment availability, many hemophilia patients have various musculoskeletal complications. A team of authors, preferentially physiotherapists, recently published a paper pondering whether the advent of new drugs will also change the position of physiotherapy in the care of patients with hemophilia.

Source: Hemophilia with Movement 21. 11. 2022

News Manual Fascial Therapy in Patients with Hemophilic Arthropathy

Fascial therapy is a rehabilitative technique that mobilizes the fascial complex using manual techniques with the goal of improving tissue mobility and function, as well as influencing pain. A team of experts from Spain evaluated the safety of this method in hemophiliacs with developed arthropathy in their study.

Source: Hemophilia with Movement 22. 4. 2021

News Individualized Prophylaxis with Achieving Higher Minimum Levels as a Possible Path to Optimal Treatment of Hemophilia A

Prophylactic administration of factor VIII (FVIII) concentrate is the standard of care for individuals with severe hemophilia A. Traditionally, the goal of prophylaxis has been to maintain minimum FVIII levels > 1%. However, it has been shown that this goal may not protect many hemophiliacs from bleeding episodes. So how does prophylaxis that maintains higher FVIII levels stand? These insights were brought by the PROPEL study, whose results were recently published in Blood magazine.

Source: Hemophilia 15. 9. 2021

News Digital Technology in COPD Therapy: Current Options and Future Prospects

This year, digital technologies have demonstrated their advantages in interpersonal communication, administrative processes, and in the field of medicine. The global crisis triggered by the coronavirus pandemic revealed the need to implement telemedicine into everyday medical practice. What are its options and future prospects in the therapy of patients with chronic obstructive pulmonary disease? These questions are thoroughly addressed in an article published in the Journal of Thoracic Disease last fall.

Source: Treatment of Asthma and COPD 1. 9. 2020

News Mental Health During the Pandemic −⁠ and How to Alleviate Its Impacts

At the symposium during the XV Spring Interactive Conference of the General Medical Society of ČLS JEP, which was eventually held in September 2021 in Prague, Prof. MUDr. Cyril Höschl, DrSc., FRCPsych, presented his lecture on the impacts of the COVID-19 pandemic on mental health. At the end of his speech, he also addressed the practical issue of selecting a suitable antidepressant.

Source: Depression and Anxiety 10. 1. 2022

News Current Data on the Safety Profile of Baricitinib in the Treatment of Rheumatoid Arthritis

Baricitinib was approved for the treatment of rheumatoid arthritis (RA) in 2017, making it essential and relevant to monitor its safety profile in clinical practice. The analysis of data collected over 8.4 years presented below provides current insights.

Source: Biological Treatment 26. 10. 2020

News Administration of Romiplostim in Patients with ITP in Real-World Practice in Central Europe

Data from the PLATON study on the administration of romiplostim in real-world clinical practice in Central and Eastern Europe confirmed very good efficacy in patients with newly diagnosed, persistent, and chronic ITP.

Source: Immune Thrombocytopenia 11. 10. 2021

News Use of Specific Inhibition of Anticoagulant Therapy During Heart Transplantation

A recent report from real clinical practice summarizes the experiences of physicians with dabigatran therapy and the reversal of its anticoagulant effect using idarucizumab in 10 patients before heart transplantation.

Source: Anticoagulant Treatment 1. 3. 2022